Cite
HARVARD Citation
Reilhac, C. et al. (2022). Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period. Diabetes, obesity & metabolism. 24 (5), pp. 838-848. [Online].